Press release
Alzheimer's Disease Pipeline, Clinical Trials Stage Products, Latest News and Releases, Collaborations, Licensing, Mergers and Acquisition, FDA Approvals 2023 (Updated)
Alzheimer's Disease Pipeline
Key Takeaways from the Alzheimer's Disease Pipeline
• DelveInsight's Alzheimer's Disease pipeline report depicts a robust space with 150+ active players working to develop 160+ pipeline therapies for Alzheimer's Disease treatment.
• The leading companies working in the Alzheimer's Disease Market include Cassava Sciences, KeifeRx, AB Science, Eli Lilly and Company, BioVie Inc., AriBio Co., Ltd., Novo Nordisk, Alector Inc., Longeveron Inc., Cognition Therapeutics, TrueBinding, Inc., AbbVie, Shanghai Hengrui Pharmaceutical Co., Ltd., and others.
• Promising Alzheimer's Disease Pipeline Therapies in the various stages of development include PM012, Lecanemab 2.5 mg/kg, Aricept (donepezil SR 23 mg), AL002, Simufilam, Allogeneic MSC, and others.
• September 2023: Cognition Therapeutics announced a study of Phase 2 clinical trials for CT1812. This is a multi-center, randomized, double-blind, placebo-controlled, parallel group 36 week multicenter Phase 2 study of two doses of CT1812 in adults with mild to moderate Alzheimer's Disease (AD).
• October 2023: Eli Lilly and Company announced a study of Phase 2 clinical trials for LY3372689. The purpose of this study is to assess the safety, tolerability and effect of study drug LY3372689 in participants with early symptomatic Alzheimer's Disease.
Request a sample and discover the recent advances in Alzheimer's Disease Treatment Drugs @ Alzheimer's Disease Pipeline Report- https://www.delveinsight.com/report-store/alzheimers-disease-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
In the Alzheimer's Disease pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Alzheimer's Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Alzheimer's Disease Overview
Alzheimer's disease is a neurodegenerative disease with insidious onset and progressive impairment of behavioral and cognitive functions including memory, comprehension, language, attention, reasoning, and judgment. It is the sixth leading cause of death in the United States.
Find out more about Alzheimer's Disease Therapeutics Assessment @ Alzheimer's Disease Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/alzheimers-disease-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Alzheimer's Disease Emerging Drugs Profile
• Nilotinib: KeifeRx
• AR1001: AriBio Co., Ltd.
• LY3372689: Eli Lilly & Co.
Alzheimer's Disease Pipeline Therapeutics Assessment
There are approx. 150+ key companies which are developing the Alzheimer's Disease therapies. The Alzheimer's Disease companies which have their Alzheimer's Disease drug candidates in the most advanced stage, i.e. phase III include, KeifeRx.
Alzheimer's Disease Pipeline Segmentation
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Learn more about the emerging Alzheimer's Disease Pipeline Therapies @ Alzheimer's Disease Clinical Trials Assessment- https://www.delveinsight.com/sample-request/alzheimers-disease-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Alzheimer's Disease Pipeline Report
• Coverage- Global
• Alzheimer's Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Alzheimer's Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Alzheimer's Disease Companies- Cassava Sciences, KeifeRx, AB Science, Eli Lilly and Company, BioVie Inc., AriBio Co., Ltd., Novo Nordisk, Alector Inc., Longeveron Inc., Cognition Therapeutics, TrueBinding, Inc., AbbVie, Shanghai Hengrui Pharmaceutical Co., Ltd., and others.
• Alzheimer's Disease Pipeline Therapies- PM012, Lecanemab 2.5 mg/kg, Aricept (donepezil SR 23 mg), AL002, Simufilam, Allogeneic MSC, and others.
Dive deep into rich insights for new drugs for Alzheimer's Disease Treatment, Visit @ Alzheimer's Disease Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/alzheimers-disease-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Alzheimer's Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Alzheimer's Disease - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Nilotinib: Novartis
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. LY3372689: Eli Lilly & Co.
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Product Name: Company Name
15. Drug profiles in the detailed report…..
16. Inactive Products
17. Alzheimer's Disease Key Companies
18. Alzheimer's Disease Key Products
19. Alzheimer's Disease- Unmet Needs
20. Alzheimer's Disease- Market Drivers and Barriers
21. Alzheimer's Disease- Future Perspectives and Conclusion
22. Alzheimer's Disease Analyst Views
23. Alzheimer's Disease Key Companies
24. Appendix
For further information on the Alzheimer's Disease Pipeline therapeutics, reach out to Alzheimer's Disease Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/alzheimers-disease-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Alzheimer's Disease Pipeline, Clinical Trials Stage Products, Latest News and Releases, Collaborations, Licensing, Mergers and Acquisition, FDA Approvals 2023 (Updated) here
News-ID: 3256294 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Alzheimer
Dementia - Alzheimer Disease Market: A Comprehensive Analysis 2030
Dementia and Alzheimer's disease represent significant challenges within the global healthcare sector. These neurological disorders, characterized by progressive cognitive decline, have seen increasing prevalence due to aging populations worldwide. This growing burden has spurred interest in the Dementia - Alzheimer's disease market, encompassing diagnostic tools, treatments, caregiving solutions, and related healthcare services. This article provides an overview of the market, its scope, current trends, and factors driving its expansion.
Data Bridge…
Alzheimer Disease Treatment Market | Allergan, Amgen, Daiichi Sankyo, Eisai
The global alzheimer disease treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the alzheimer disease treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth…
United States Alzheimer Drugs Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "United States Alzheimer Drugs Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly…
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is…
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,…
Global Alzheimer Market Report: 2015 Edition | Now Available at Researchmoz.us
Researchmoz added Most up-to-date research on "Global Alzheimer Market Report: 2015 Edition" to its huge collection of research reports.
Alzheimer’s disease is defined as an advanced neurological disorder that increasingly deprives patients of their memory and ability to carry out daily activities. As it grows in a human brain, individuals are likely to practice difficulties in linguistic, agility and insight along with negative changes in the character and performance such as…
